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The onset search for differential protein expression in endometriosis commenced 
more than 30 years ago, when the gel electrophoresis could not be available to distin-
guish serum from women with and without disease. Gradually as the proteomics allows 
the comprehensive analysis of peritoneal fluid, serum and tissue samples with good 
sensitivity and resolution, it has promised in delivering markers possibility associated 
with endometriosis. Cytokines and growth factors that are present in serum, peritoneal 
fluid, endometrium, endometriotic lesions tissues and involved in tissue implant-
ing process including hormone regulation, angiogenesis, invading and malignancy 
may be the focus to develop the noninvasive diagnostic test and possible treatment 
target for endometriosis. Individual peptides or proteins that are present or absent (or 
up- or down-regulated) in various conditions can be assessed as possible biomarkers. 
Alternatively, proteomic profiling, using mass spectrometry in combination with bioin-
formatics software to identify the actual protein and peptide pattern can be used as a 
distinctive marker to diagnostic and treatment target contribution to the disease.
Keywords: diagnosis, treatment, endometriosis
1. Introduction
Endometriosis (EM) is defined as a benign condition of gynecological diseases 
when endometrial debris including gland and stroma components outside the 
uterus and spread to pelvis and extrapelvic sites. It affects at least 10% reproductive 
women with approximately 70% of cases developing pelvic inflammatory disease 
and 25–30% of cases associated with infertility [1]. The classical symptoms are 
dysmenorrhea, chronic pelvic pain, and ovarian chocolate cysts.
Till now, the pathogenesis of endometriosis is unclear. The retrograde menstrua-
tion is the basic theory which the menstrual fragments mostly attach to the perito-
neum or ovaries area [2]. Whereafter endometriosis mainly responds to fluctuations 
in estrogen and progesterone by growth and inflammation. And endometriosis 
mostly involves in the reproductive tract components, such as ovaries, fallopian 
tubes, uterosacral ligaments, cervix, recto-vaginal septum and vagina. There are 
commonly exhibited with fibrous walls, adhering to the neighbor structures and 
usually containing chocolate-colored content. Therefore the affected organs are 
forming together with serial symptoms-dysmenorrhoea, ovarian chocolate cysts 
and infertility are often found in the patients. Recently, stem cell theory can be 
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considered as perspective view of the retrograde menstruation theory [3]. Other 
theories like immune system dysfunction, genetic susceptibility and exposure to the 
environment such as dioxins can devote to the progress of the disease [4, 5].
Generally, severity of endometriosis is classified by the revised American 
Fertility Society (rAFS) system [6], dividing patients into one of four stages (I–IV, 
minimal-severe) based on lesion size and pelvic adhesions associated with infertil-
ity. However, it remains uncertain whether the disease progresses through these 
stages. Actually some surgeon would prefer to stage on the basis of the sites and 
extent of the lesions under the laparoscopy or laparotomy and describe without 
AFS or r-AFS stage. Sometimes they may give some complementary suggestion [7]. 
Meanwhile, endometriosis has a variable symptom profile which does not relate 
with severity of this disease [8]. Furthermore, the patients often suffer from the 
symptoms of infertility or chronic pain for several years before the diagnosis is 
lately confirmed. So it makes the clinical diagnosis even more difficult. And actu-
ally there has been a lack of precise diagnosis method in previous researches. On 
the aspects of clinical application and financial consideration, more effective and 
noninvasive test will be needed in endometriosis disease.
Currently, laparoscopy offers the most widely accepted technique and method 
for evaluating and treating endometriosis. And most of endometriosis patients are 
treated by surgical removal of lesions and/or hormonal suppression focused on 
reducing estrogen, such as progestins, androgens, gonadotropin-releasing hormone 
(GnRH) agonists, and recent aromatase inhibitors. However, both approaches 
are associated with various side effects and a highly recurrent incidence [9, 10]. 
Therefore, identification of protein molecular mechanisms involved in the patho-
genesis of endometriosis and strategic therapies for treatment are critical.
2. Protein molecular mechanism involving in endometriosis
There should be some factors present in the ectopic lesions of endometriosis, 
peritoneal fluid and blood that stimulate the lesion to proliferate, implant and invade 
[11, 12]. And comparing with eutopic endometrium, endometriosis lesions has 
different biochemical and functional expression including steroid receptivity and 
invasive potential [13]. Over all, the specific markers of endometriosis may be classi-
fied into three main categories: (i) serum and/or peritoneal: growth factors, cytokines, 
hormones, glycoproteins, proteolytic enzymes and their specific inhibitors, soluble 
adhesion molecules, autoantibodies and environmental contaminants. (ii) endometrial 
and biochemical-endometrial: stromal, glandular, neuronal, hormonal receptors, 
mesenchymal stem cells, proteolytic enzymes and their specific inhibitors, adhesion 
molecules, osteopontin.(iii) genetic types: oxidative stress genes, tumor suppressor 
genes, oncogenes, regulatory genes, DNA repair genes, chromosomal aberrations or 
amplifications, loss of heterozygosity, genetic polymorphism of variable genes, and 
genome-wide alterations. And we show the focus continuously.
2.1 Hormones regulation proteins in the pathogenesis of endometriosis
Steroid hormones play an important role in endometriosis physiology and 
pathology. The production of cytokines in endometriosis is the altered responsive-
ness to progesterone, showing a characteristic very low expression of progesterone 
receptor A (PR-A) and the absence of PR-B in rodent models, and with decreased 
PR-B/A ratio and reduced PR-B immunoreactivity, demonstrated in human 
endometriosis lesions [14, 15]. Hormonal dependence in endometriosis is demon-
strated by an increased ER-β expression (approximately 100 times), due to altered 
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methylation in the ESR2 gene promoter [16]. In experimental model of endometrio-
sis, ER-β may be involved in inhibiting apoptosis and increasing cytokine produc-
tion in endometriosis, such as MCP-5, IL-1b and IL-16, which seem to enhance 
cells adhesion and proliferation [17]. The secretion of PGE2 is regulated by MIF 
through stimulating COX-2 activity. PGE2 is considered to be one of the main pro-
inflammatory regulating factors which appears to be confirmed by its elevated level 
in endometriosis tissues of human being [18].
2.2 Proteins of angiogenesis process of endometrial tissue
On behalf of endometriosis lesions, neovascularization and angiogenesis factors 
should be introduced. Angiogenic factors such as VEGF [19], ENDO-I [20], angio-
genin [21], pleiotrophin, midkine [22], PGF [23], angiopoietin [24], and glycodelin 
[25, 26] have been identified association with the lesions angiogenesis in endo-
metriosis. Angiogenic activity is supplemented by the co-existence of pathologic 
angiogenesis, immune suppression, and immune activation. Study from human 
being indicated the correlation between high MVD and symptom of pelvic pain in 
patients with endometriosis by transvaginal color doppler ultrasound evaluation. 
MVD has been described using immunohistochemical evaluation with CD34-
labeled endothelial cells of vessels [27, 28]. There was no significantly increased 
VEGF expression but it has been found in the involvement of other angiogenic fac-
tors with the active implants showing high mitotic index and increased MVD [27]. 
Further findings were reported in other articles that VEGF-A role was demonstrated 
by its increased concentrations in the endometrium of patients with endometriosis. 
Moreover, it was confirmed that the expression of VEGF-A gene was higher in 
peritoneal endometriosis compared with normal peritoneum [29].
2.3 Proteins in invading process of endometrial tissue
In endometriosis, after the attachment to the ectopic sites, the epithelial endome-
trial cells invade to the extracellular matrix with MMPs and TIMPs secretion playing 
an important role in degradation in extracellular matrix and basement membrane 
components [30]. It has been proved that this process is related to the involvement of 
MMPs, which is stimulated by TNF-a and IL-1 at high concentrations in peritoneal 
fluid. Meanwhile, TNF-a inhibits TIMP-1 and TIMP-2, leading to an imbalance of 
MMPs/TIMPs ratio. In patients of endometriosis, MMP-2 and membranous type 1 
of eutopic endometrium have been found higher, TIMP-2 was lower than normal 
women [31]. Increased MT5- MMP expression and alterations of the balances 
between MMP-9/TIMP-1, MMP-9/TIMP-3, MMP-3/uPA, VEGF/MMP-3/uPA, 
VEGF/ /MMP-2/CD44/Ki67, PAI/TIMP-1, and IL-1/ /MMP-1 indicated that implan-
tation and invasion might participate the mechanism of endometriosis [32–38].
2.4 Proteins in carcinogenesis possibility of endometriosis
Clinicopathological, molecular, and genetic evidences support the hypothesis of 
endometriosis as a neoplastic process, with a potential to malignant transformation. 
Polypoid endometriosis, premalignant changes, borderline tumors and malignant 
tumors were described. Except for an increased MMPs expression associated to 
deregulation of the intercellular adherence signaling, tumor suppressor genes, 
oncogenes, CAMs, furthermore LOH and inflammatory immunomodulation were 
detected [39, 40]. The progressive accumulations of genetic alterations of tumor-
suppressing genes and oncogenes are probably responsible for endometriosis devel-
opment and its possible association with the development of malignancies [41–45].
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2.5 Proteins involving in peritoneal fluid and plasma of endometriosis
Most of researches have demonstrated that macrophages, lymphocytes, endo-
metrial cells and mesothelial cells are able to produce cytokines and inflammatory 
mediators such as ILs [3, 46, 47], TNF-a [48], PGF2, PGE2 and thromboxane B2 [49], 
MCP-1 [50], RANTES [51], eotaxin [52], GROa [47], SDF1 [53], and MIF [50, 54]. 
The main process is leading to the stimulation of endometriotic cells proliferation 
and adhesion to ectopic sites, angiogenesis, and stimulation of the release of other 
cytokines and chemokines, later amplifying their effects.
Macrophages can amplify the activity of COX-2 and PGE2, which results in 
VEGF stimulation in endothelial cells from endometriotic lesions, together with 
factor StAR, association with an increased estrogen level in the endometrial tissue 
[55–57]. PGE2 suppresses the activity of phagocytes, that allowing endometriotic 
implants formatting [58]. Estrogens and PGE2 can induce FGF-9 expression which 
can further activate endometrial cells proliferation, paralleling to the stimulation of 
angiogenesis and apoptosis inhibition at the same time. Lymphocytes are involved 
in various cytokines production with potential role in endometriosis lesions 
implanting. Whether in vitro study or in human endometriosis, Th2 cells of perito-
neal fluid were shown to stimulate the secretion of IL-4 and IL-10. NK cell-medi-
ated cytotoxicity, commonly manifested by lymphocytes adherence to endometrial 
cells through LFA-1 — ICAM-1 pathway and their presentation as targets to NK 
cells, may fail in endometriosis [59, 60]. This indicated the possible mechanism that 
sICAM-1 may bind to LFA-1 expressing in lymphocytes can prevent endometrial 
cells recognition involved in endometriosis pathogenesis.
TNF-a is a typical pro-inflammatory cytokine produced by macrophages, which 
can exhibit high levels in serum and peritoneal fluid of patients with endometrio-
sis [61, 62]. Recent studies have shown that TNF-a-induced activation of IKKb 
complex leads to the initiation and progression of endometriosis by enhancing the 
survival rate of ectopic epithelial cells rather than stromal cells and not eutopic 
epithelial cells [63]. MIF, another cytokine, has been shown a high level in the 
peritoneal fluid, in serum samples, and in peritoneal macrophages, its secretion 
being regulated by estrogens in endometriosis [85]. MIF can stimulate endothelial 
cell proliferation, endometriotic lesions survival, expressing VEGF, IL-8, PGE2, 
COX-2, MCP-1, aromatase, and resulting back in stimulating TNF-a in endometrial 
cells [18, 64]. That is why in experimental models, MIF antagonist significantly 
reduces lesions size of endometriosis by inhibiting cell adhesion, tissue remodeling, 
angiogenesis, and inflammation, in addition to routine alteration of the balance 
between pro- and anti-apoptotic factors [65].
3. Progress in proteomics
It is recognized that gene expression changes does not reflect the changes in protein 
expression within the cell. Better tools are needed to accurately probe the protein 
activities and levels. Protein arrays are arguably underachieving their potentials as 
they are perceived not as precise as DNA arrays. Functional proteomics still holds 
great promises that it could result in greater understandings of the mechanism of 
disease. The goals proteomics of diseases are to improve molecular classification of 
diseases and to discover molecular biomarkers for their diagnosis, treatment target 
and following up [66–68]. Better tools are needed to accurately calculate the protein 
activity levels. Protein arrays (used synonymously with protein microarrays or protein 
biochips) are one of the solutions to the high throughput study of protein interaction 
networks or immune reactivity [69–71]. Mass spectroscopy (MS) [72], relies mainly 
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on the mass-to-charge ratios to distinguish different proteins. It is widely used as a dis-
covery tool of diagnostic, prognostic, and therapeutic protein biomarkers. Moreover, 
it does not need to identify molecules. And protein arrays depend on the availability of 
specific recognition molecules. MS-based methods can simultaneously screen numer-
ous proteins, but its sensitivity is approximately 1 ng/mL. Emerging protein arrays 
based on magneto-nanosensors enable to study many proteins to proteins interactions 
simultaneous easily with sensitivity low than about 1 pg/mL. Proteomic researches 
mainly includes the 2-DE reference map and a database by proteomic comparison 
between healthy persons and patients. Comparing to western blot, 2-DE can be used 
to find out autoantigens that may induced autoantibodies in some diseases.
3.1 Protein arrays
Protein arrays with antibodies are developing a tool for rapid measurement of 
abundance of proteins expression. It makes the possibility to screen the aimed proteins 
changes in different diseases and biological processes. In most cases, this approach 
depends on exposing serum samples from patients to an ordered array of antigens, 
capturing those antibodies that bind the antigens on the arrays. Immobilization of 
proteins on the surface of arrays and neutralizing reactive areas after the immobiliza-
tion are important practical issues in protein array. Many different types of proteins 
arrays such as antibody arrays and peptide arrays have been reported [73]. It starts 
research in breast cancer and leukemia [74, 75]. Recently, one of the protein array 
technologies is the magneto-nanosensor array where giant magnetoresistive (GMR) 
[76] sensors are used to quantitatively measure analyte of interest proteins which 
are labeled with magnetic nanoparticles (MNP). Another emerging protein array 
technology is Nucleic Acid Programmable Protein Arrays (NAPPA) [77], which have 
thousands of protein features directly expressed by nucleic acids on array surface.
More attentions have been paid to the role of protein arrays in medicine. They can 
be used for early detection of diseases, diagnosis of stages, stratification of patients, 
and prediction of therapeutic effects, and are increasing realization of the vision of 
personalized medicine. For cytokine measurements, protein arrays should be improved 
in both functional sensitivity and probe density. Till now, the arrays have two major 
drawbacks: first, they are biased, because antigen selection is based on their potential 
to play a role in disease. Secondly, the analytical comprehensiveness of this technique is 
limited because only the molecules represented on the array can be identified.
3.2 Mass spectrometry (MS)
In the past few decades, the paradigm of biomarker research has shifted from 
a hypothesis-driven approach to a discovery-driven approach. Mass spectrometry 
and separation techniques and proteomics methods have been fully developed and 
have been common. Particularly when two-dimensional liquid chromatography/
tandem mass spectrometry, or two-dimensional gel electrophoresis (2-DE) and 
matrix laser desorption ionization time of flight mass spectrometry (MALDI-
TOF-MS) combination, followed by database search (sequence tags or peptide mass 
fingerprints) are widely used. These methods greatly increase the comprehensive-
ness of protein identification.
Identify disease-associated antigens can elicit through immune responses by 
combining protein separation (2-DE, gel-free separation), immunological detection 
(Western blotting) and MS, or combining immunocapture and MS [78]. Proteins 
derived from cells or tissues (e.g., cancer cells) are separated by 2-DE, and antigen 
proteins are detected by applying patient serum, which may include disease-specific 
antibodies followed by enzyme-labeled secondary antibodies. In order to identify 
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immunogenic proteins, the corresponding spots are separated from the gel and 
gels were digested. MS or tandem mass spectrometry is used for analysis and then 
analyzed by peptide fingerprinting or sequence tags method.
3.2.1 Isotope-coded affinity tagging multidimensional LC-MS
LC–MS makes identification and quantification of target protein possible in a 
large and complex sample and most of the time it may not be achieved in the clinical 
work. However, it will be useful when proteins are limited in a sample and at pres-
ent this method will be considered as a supplement to 2-DE gel [79, 80].
3.2.2 MALDI-MS
Antigen analysis of immunocapture MS is derived from the immobilization of 
antibodies in the serum of patients. Almost all antibodies are captured on protein 
A or G, which is a bacterial derived protein with specific affinity for the Fc domain 
of the antibody. Protein mixtures (cell or tissue lysates) are applied to a column or 
bead immobilized with antibodies to capture specific antigens of antibodies pres-
ent in patient samples. Finally, the proteins were identified by MALDI-TOF-MS 
or surface enhanced laser desorption/ionization mass spectrometry (SELDI-MS). 
In SELDI-MS, the protein is enzymatically cleaved into a peptide mixture and 
undergoes MS. It can be a fully automated system allowing high-throughput and 
rapid identification. MS afford a method to identify a protein even from a complex 
mixture of proteins [81, 82]. It is preferred and an applicable for a pure protein or a 
single spot for 2-DE gel.
3.2.3 Surface-enhanced laser desorption/ionization (SELDI-MS)
Chemical defined or antibodies-coated protein biochip arrays for rapid protein 
detection. This system is used when small amount of samples is available. Very high 
surface expression of the immunoglobulin binding protein (proACTR) as the antigen 
capture and transfer reagent [83]. ProACTR can immobilize the antibody through the 
Fc region of antibody, and allows for higher capture capacity than antibody-coated 
beads. Captured antigens can be directly transferred to a platform for MS analysis 
(SELDI-TOF-MS). It starts its diagnosis research with post-translationally modified 
proteins and high-throughput technique in breast cancer, lung cancer and prostate 
cancer. Unfortunately, it does not allow reliable protein sometimes [84, 85]. To the 
best of our knowledge, immunoproteomics with proACTR has not yet been applied 
to profile antigens associated with a certain disease, but mainly to the quantification 
of a single target [86, 87].
4. Applications and experiences in the past
The 2-DE for tissue sample is more complex than that for serum. Tissue 
from ovarian chocolate cysts or from eutopic endometrium contains connective 
tissues, red blood cells, epithelial cells and stromal cells. Stringent protocols are 
adopted to ensure uniformity throughout the process to facilitate the protein 
maps. However, the development of robust assay platforms and standardized 
protocols are required before MS-based antigen profiling can be performed in the 
clinical setting.
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4.1 Expression and significance of peritoneal fluid protein in patients  
with endometriosis
In 2003, Tabibzadeh et al. [88] used two-dimensional gel electrophoresis to analyze 
the protein profile of peritoneal fluid in 12 patients with EMs (6 cases were mild and 
6 cases were severe degree). However, 12 cases of non-EMs ascites were analyzed as 
control (6 cases of infertility, 6 cases of normal fertile). There was no significant differ-
ence between the infertile controls and the normal fertile control group. However, the 
patients with mild EMs had protein reductions associated with several peritoneal pro-
tein spots of approximate molecular weights of 35–40 kD and pI close to 5.7–6.0. and 
the reduction in severe EMs cases was more markedly apparent. Consistent with these 
data, enzyme-linked immunosorbent assay showed that severe endometriosis was 
associated with markedly elevated levels of IL-10 in the peritoneal fluid. Endometriosis 
maybe associated with disturbed secretion of proteins into the peritoneal cavity and 
with an elevated level of IL-10 in the peritoneal fluid. Most of these proteins have 
not been further described in the existing literatures, so it is still unclear whether the 
aforementioned results can be used as diagnostic markers for EMs.
Ferrero et al. [89] used two-dimensional gel electrophoresis, silver stained, 
semiquantitative computerized analysis the changes of protein expression profile 
in the peritoneal fluid and plasma of 72 patients with EMs and 35 infertile control 
patients. Compared with the controls, one beta chain isoform (HpbetaE; molecular 
weight 38.40 ± 0.94 kD; and isoelectric point, 5.63 ± 0.17) had significantly higher 
expression in women with endometriosis. HpbetaE level was found no significant 
difference between mild endometriosis (rAFS, stage I-II) and severe endometrio-
sis (rAFS, stage III-IV). But the expression of HpbetaE in the control group was 
obtained to be related to the stage of menstrual cycle. The above studies indicate that 
changes in the protein expression profile of patients with endometriosis. In 2007, Liu 
et al. [90] used SELD I-TOF-MS technology and its associated protein chip to detect 
the plasma protein profiles from 36 patients of endometriosis and 35 healthy indi-
viduals. 21 differentially expressed protein peaks were found and three protein peaks 
were established. The endometriosis diagnostic model had a sensitivity of 91.7% and 
a specificity of 82.9%, and was performed on 16 healthy subjects and 15 patients. 
The sensitivity was 87.5% and the specificity was 80%. It provides an approach for 
screening the plasma markers of endometriosis. In 2007, Ferrero et al. [91] used 
two-dimensional gel electrophoresis; protein spots of interest were identified by 
liquid chromatography tandem mass spectrometry to study the differential expres-
sion of peritoneal fluid proteins in patients with and without endometriosis. Several 
molecules had aberrant expression in peritoneal fluid of women with endometriosis 
may be useful for a better understanding of the pathogenesis of this disease.
In 2006, Zhang et al. [92] applied two-dimensional gel electrophoresis (2-DE), 
Western blotting, and mass spectrometry (MS) technology to study proteins in 
endometriosis and normal controls, and analyzed differences using Western blots. 
The normal human serum and patient serum were compared with the total protein 
of endometriosis. In patients with endometriosis, 13 protein spots were associated 
with 11 known proteins, while 11 protein spots were found differently expressed in 
the endometrium of patients with and without endometriosis. Some proteins may 
be cytoskeleton, some may regulate in cell cycle, signal transduction or immune 
function participation. The hybridization of vimentin, beta-actin and ATP synthase 
beta subunit in serum of patients with endometriosis was significantly different 
from that of normal serum. Three different points were used to determine the pro-
tein expression profile, vimentin, β-actin, and ATP synthase β subunits respectively. 
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ATP synthase may play an important role in ectopic endometrium as it needs 
invasive, and cell adhesion and cytoskeletal remodeling. Vimentin and β-actin is a 
cytoskeletal protein. Studies have shown that the expression of these proteins is up-
regulated in the endometrium in patients with endometriosis. These proteins have a 
certain effect on the formation of endometriotic lesions. Given that the occurrence 
of endometriosis may be due to an abnormality of eutopic endometrium itself. In 
2007 and 2008, Liang [93] and others used surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology to study 
serum protein expression in patients with endometriosis and healthy controls. A 
diagnostic model consisting of 5 protein peaks was established with a sensitivity of 
91.7% and a specificity of 90.0% provides new prospect for screening endometrio-
sis markers. In 2007, Liu et al. [90] also used SELDI-TOF-MS technology to study 
plasma protein expression in patients with endometriosis and healthy controls. It 
was found that 20 protein peaks were elevated or decreased in both of them. The 
sensitivity was 87.5% and the specificity was 80.0%.
4.2 Expression and significance of tissue protein in patients with Endometriosis
In 2006, Kyama et al. [5] used SELD I-TOF-MS technology to find that the 
expression of proteins and peptides in the eutopic endometrium of patients with 
endometriosis weight range of 2.8–12.3 kDa was 3–24 times lower than the molecu-
lar with non endometriosis. The expression of proteins and peptides in the lesions of 
patients with endometriosis had a tendency to increase within the molecular weight 
range of 3–96 kDa, and especially an up-regulated cluster of proteins between 22 
and 23 kDa, identified to be transgelin, a smooth muscle actin-binding protein. In 
2007 Fowler et al. [94] used 2-DE and peptide mass (MS) technology to confirm 
that the protein associated with endometriosis. Several deregulated proteins are 
identified: (1) chaperones and calcium binding proteins include heat shock protein 
90 (HSP90) and annexin A2. (2) Cell oxygenation status related to protein, such 
as peroxiredoxin and thioredoxin-1, -2 (thioredoxin reductase-1, -). (3) Proteins 
associated with protein/DNA synthesis/decomposition, such as nucleoside diphos-
phate reductase, prohibitin, and proline-4-hydroxylase. (4) Secreted proteins, such 
as apolipoprotein A1. (5) Structural proteins such as vimentin and actin, whose 
function suggests that they play a role in the pathogenesis of endometriosis. At the 
same time, it was believed that the differentially expressed protein spots produced 
are identical whether the lysate of the endometrium was aggregated or isolated. 
Immunohistochemistry, Western blotting, and biological effects were also used to 
validate differential proteins and achieve desirable results. This study demonstrated 
that 2-DE gel analysis and mass spectroscopic protein identification are suitable for 
the identification of proteins with candidate associations with endometriosis.
4.3 Endometriosis infertility protein detection
Previous result of our group indicated [95] that 76 eutopic endometrial polyps 
cases of endometriosis group histologically resembled endometrial polyps but the 
majority of endometrial polyps with endometriosis occurred in primary infertility 
cases and in fewer pregnancy rate women who had stable and smaller EPs without 
association with the AFS stage. The recurrence rate of endometrial polyps with 
endometriosis group was higher than that in non endometriosis group. In 2009, 
Ferrero et al. [96] reported the peritoneal fluid proteome collected under laparos-
copy from 26 fertile women and 26 infertile ones With endometriosis. One isoform 
of immunoglobulin light chain spot and 9 protein spots had been found significantly 
higher expression in PF of infertile patients than infertile controls by applied with 
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2-dimensional gel electrophoresis (2-DE) with computerized analysis and protein 
spots were identified by liquid chromatography tandem mass spectrometry (MS). 
No protein spots had significantly lower expression and 3 protein spots remain 
unidentified.
4.4 Proteomics detection of animal models of endometriosis
Many animals such as rhesus monkeys, rabbits, and nude mice have been used 
as models for studying endometriosis, but most of these animals have no menstrual 
cycle, and only primates can spontaneously produce endometriosis with regular 
menstrual cycles and menstrual blood flow. Their pathogenesis and pathological 
features are similar to those of humans. Monkey experiments have confirmed that 
current menstrual bleeding can cause pelvic lesions. In 1991, Sharpe et al. [97] first 
reported using two-dimensional electrophoresis (2-DE) to observe that surgi-
cally induced ectopic endometrium in rats lacked progesterone-induced secretory 
uterin protein 21 (PUP21, MW 70 kDa, p I 5. 7), whereas normal endometrium 
expression of the protein suggests that PUP21 deficiency is associated with reduced 
fertility in patients with endometriosis. In 1993, Sharpe et al. [98] also used two-
dimensional electrophoresis to study the rat endometriosis implanted by surgery. It 
was found that ectopic endometrium specifically expressed two groups of proteins: 
ENDO I (MW 40–50 kDa, p I 4. 0–5. 2) and ENDO II (MW 28–32 kDa, p I 7.5–9.0). 
Further studies using amino acid sequence analysis confirmed that ENDO-2 is 
TIMP-1 and ENDO-1 is haptoglobin-like. Studies have shown that endometriotic 
lesions secrete haptoglobin in combination with macrophages to reduce their 
adherent phagocytic capacity, so that intimal ectopic cells cannot be eliminated, 
but haptoglobin can stimulate macrophages to secrete inflammatory cytokines such 
as IL-1, − 6 and TNF, IL-6 can up-regulate ectopic endometrium cells to express 
haptoglobin, forming a positive feedback in the lesion, thereby promoting the 
progression of endometriosis. In the peritoneal fluid and serum of patients with 
endometriosis, the concentration of TIMP-1 was significantly reduced. Therefore, 
the abnormal expression of TIMP-1 may be one of the causes of the onset of endo-
metriosis, and may become a potential marker for diagnosing this disease.
5. Possible directions in the future
Once we have discovered one or more proteins that are specifically expressed in 
patients with endometriosis, the next step is to develop them as a diagnostic test for 
it. The diagnostic method must have good sensitivity, specificity, positive predic-
tive value, and negative predictive value. What we need to overcome is not only the 
individual differences in the population, but also the differences in specific tissue 
protein components and the effects of natural menstrual cycles or hormone effects. 
Protein chip, protein array mass spectrometry technique have been used to perform 
a comprehensive search of protein expression profiles of endometriosis patients in 
order to find a group of proteins with high sensitivity and specificity. Applying the 
changes in the expression of this group of proteins to diagnose and predict disease 
will undoubtedly bring about a new endometriosis diagnosis field.
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